Journal article

Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach

Michelle R Ananda-Rajah, Allen Cheng, C Orla Morrissey, Tim Spelman, Michael Dooley, A Munro Neville, Monica Slavin

Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2011

Abstract

Studies using patient-level data to determine the attributable cost of invasive fungal diseases (IFDs) are few. Using a case-control study with activity-based costing of patients admitted to a quaternary hospital from 2002 to 2007, we determined attributable hospitalization cost (and 12 weeks thereafter), length of stay (LOS), and costly antifungal treatment (C-AT; liposomal amphotericin B, voriconazole, posaconazole, caspofungin), expressed as defined daily doses (DDDs) per IFD episode, in patients with hematological malignancies and hematopoietic stem cell recipients. Matching criteria and median regression modeling controlled for confounding variables, including LOS prior to IFD onset. Mu..

View full abstract

Grants

Funding Acknowledgements

This study was partially funded by Schering-Plough Pty. Ltd. using an unrestricted educational grant. Michelle R. Ananda-Rajah is the recipient of a National Health and Medical Research Council postgraduate medical scholarship.M.R. A.-R. has received speaker's fees from Schering Plough Pty. Ltd. to formally present the results of this study; C.O.M. serves or has served on advisory boards for, has received investigator-initiated grants from, and has given lectures for Gilead Sciences, Pfizer, Merck, and Schering Plough; A.C., T.S., and M.D. have no conflicts; A.M.N. has received contractual funding from Schering Plough Pty. Ltd.; and M.S. serves or has served on advisory boards for, has received investigator-initiated grants from, and has given lectures for Gilead Sciences, Pfizer, Merck, and Schering Plough.